HIF-PHIs for Anemia Management in CKD
Clinical Journal of The American Society of Nephrology（2022）
摘要
The introduction of recombinant human erythropoietin in 1989 was a watershed moment in the care of people with advanced CKD, dramatically decreasing transfusion requirements and potentially improving quality of life, particularly among individuals with severe anemia ([1][1]), while reducing
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要